Drug news
CHMP recommends approval of Lojuxta (Aegerion Pharmaceuticals) for HoFH
The European Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Lojuxta (lomitapide), from Aegerion Pharmaceuticals, as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with Homozygous Familial Hypercholesterolemia (HoFH).
The drug was approved by the FDA in December 2012 under the name Juxtapid.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins